This study will evaluate MRI brain atrophy, [18F]FDG-PET and CSF-total-tau and their usefulness in assessing risk of clinical progression in patients referred to a memory clinic under suspicion of neurodegenerative disease. The gene discussed is MAPT; the disease is neurodegenerative disease.